- |||||||||| dexamethasone / Generic mfg.
Trial completion date, Trial primary completion date: Anosmia and / or Ageusia and Early Corticosteroid Use (clinicaltrials.gov) - Sep 6, 2023 P4, N=300, Recruiting, Trial completion date: Mar 2023 --> Oct 2023 Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Jan 2023 --> Nov 2023
- |||||||||| prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Trial completion date, Trial primary completion date: Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques (clinicaltrials.gov) - Sep 6, 2023 P2, N=30, Recruiting, Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Mar 2024 Trial completion date: Dec 2024 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2028
- |||||||||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Enrollment closed, Enrollment change, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Sep 6, 2023 P2, N=7, Active, not recruiting, N=96 --> 64 Suspended --> Active, not recruiting | N=60 --> 7
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: MPAL: Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Sep 5, 2023
P2, N=18, Completed, Recruiting --> Completed Recruiting --> Completed | N=60 --> 18 | Trial completion date: Dec 2034 --> Feb 2023 | Trial primary completion date: Dec 2034 --> Feb 2023
- |||||||||| moxifloxacin intravenous / Generic mfg.
Journal, Surgery: RETINAL DEPOSITS OF TRIAMCINOLONE-MOXIFLOXACIN AFTER DROPLESS CATARACT SURGERY. (Pubmed Central) - Sep 2, 2023 These epiretinal crystalline deposits are benign and generally do not interfere with visual acuity. Nevertheless, clinicians should be aware of this differential diagnosis because clinical misdiagnosis can lead to unwarranted evaluation and treatment.
- |||||||||| triamcinolone acetonide / Generic mfg.
Trial initiation date: Comparison of two treatment modalities for managing oral lichen planus. (EUDRACT) - Sep 2, 2023 P=N/A, N=16, Completed, Long-standing nasolacrimal duct hardware may allow reflux of nasopharyngeal and nasolacrimal bacteria, contaminating the ocular surface during surgery. Initiation date: Jul 2000 --> Jul 2019
- |||||||||| fluocinolone acetonide / Generic mfg.
Review, Journal: Corticosteroid implants for chronic non-infectious uveitis. (Pubmed Central) - Sep 2, 2023 To better understand the efficacy and safety profiles of corticosteroid implants, we need future trials that examine implants of different doses, used for different durations. The trials should measure core standard outcomes that are universally defined, and measured at comparable follow-up time points.
- |||||||||| dexamethasone / Generic mfg.
Journal: The progress in multiple myeloma. (Pubmed Central) - Sep 2, 2023 In general, the recommended induction therapy is a triplet or quadruplet-agent therapy consisting of a proteasome inhibitor, an immunomodulatory compound, and/or a CD38 antibody in combination with dexamethasone...Although the prognosis for patients with MM has significantly improved over time due to advances in treatment, the disease remains incurable and relapses are common. Because various immunotherapeutic agents, new drugs and combinations have become available, selecting the most effective treatment for patients with relapsed/refractory MM needs both art and science.
- |||||||||| Nevanac (nepafenac) / Novartis
Journal: The Effects of Uneventful Phacoemulsification on Subfoveal Choroidal Thickness. (Pubmed Central) - Sep 1, 2023 In patients with moderately active ulcerative colitis, there was no difference in the efficacy and safety of tofacitinib and oral prednisolone for induction of remission at 8 weeks. Phacoemulsification can alter choroidal thickness until at least 3
- |||||||||| dexamethasone / Generic mfg., fluticasone / Generic mfg.
Journal: A comparative study of human and zebrafish glucocorticoid receptor activities of natural and pharmaceutical steroids. (Pubmed Central) - Sep 1, 2023 The other steroids tested, androgens and progestins, are all antagonists of both GRs with equal or lower potency on zfGR than on hGR. Surprisingly, the lower efficacy and potency on zfGR of aldosterone, forbimenol and the dissociated glucocorticoids is not related to their affinity for the receptors which would suggest that it could be related to less efficacious recruitment of coactivators by zfGR compared to hGR.
- |||||||||| hydrocortisone / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study) (clinicaltrials.gov) - Sep 1, 2023 P3, N=44, Active, not recruiting, Recruiting --> Active, not recruiting | N=36 --> 22 Recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2025
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Unusual Presentation of Primary Splenic Lymphoma: A Case Report (LEVEL 3, GENERAL ASSEMBLY) - Aug 31, 2023 - Abstract #SOHO2023SOHO_748; PSL presenting with secondary HLH is rare. Early diagnosis and early treatment are important to avoid a lethal outcome.
- |||||||||| dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
Retrospective data, Review, Journal: Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis. (Pubmed Central) - Aug 31, 2023 There is insufficient evidence to guide this therapy with regard to plausible adverse long-term outcomes. Further RCTs with direct comparisons between systemic corticosteroid treatments are needed to determine the optimal treatment approach, and these studies should be adequately powered to evaluate survival without major neurosensory disability.
- |||||||||| abiraterone acetate / Generic mfg.
Biomarker, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Aug 31, 2023 P2/3, N=600, Active, not recruiting, Trial completion date: Aug 2026 --> Feb 2028 | Trial primary completion date: Jul 2024 --> Aug 2025 Phase classification: P1 --> P2/3 | N=20 --> 600 | Trial completion date: Oct 2023 --> May 2024 | Trial primary completion date: Oct 2023 --> May 2024
|